Incremental prognostic value of changes in B-type natriuretic peptide in heart failure

Roberto Latini, Serge Masson, Maylene Wong, Simona Barlera, Elisa Carretta, Lidia Staszewsky, Tarciso Vago, Aldo P. Maggioni, Inder S. Anand, Lip B. Tan, Gianni Tognoni, Jay N. Cohn

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

PURPOSE: B-type natriuretic peptide is one of the most sensitive and specific biohumoral markers of heart failure. We hypothesized that B-type natriuretic peptide changes during treatment of heart failure may provide independent information on disease progression and outcome in patients enrolled in the Val-HeFT trial. METHODS: Patients were divided into four groups according to concentrations of B-type natriuretic peptide at baseline versus 4 months (n = 3740) or 12 months (n = 3343), with respect to the baseline median (97 pg/mL): low→low (stable below median, 44%-46%), high→high (stable above median, 32%-37%), high→low (above to below median, 12%-14%), and low→high (below to above median, 6%-9%). Cox multivariate regression analysis was used to assess the risk of death and morbidity, with adjustment for baseline B-type natriuretic peptide concentrations. RESULTS: Patients who improved their B-type natriuretic peptide at 4 months (high→low) had a similar risk for mortality (hazard ratio = 1.191, 95% confidence interval [CI] 0.870-1.631, P =.2746) compared with the low→low patients. Conversely, patients who worsened in their B-type natriuretic peptide (low→high) had a risk for mortality (hazard ratio 2.578, CI, 1.861-3.571, P 2 increase in left ventricular end-diastolic diameter, whereas it decreased by 0.10 cm/m2 in high→low and low→low groups (P

Original languageEnglish
JournalAmerican Journal of Medicine
Volume119
Issue number1
DOIs
Publication statusPublished - Jan 2006

Fingerprint

Brain Natriuretic Peptide
Heart Failure
Confidence Intervals
Mortality
Treatment Failure
Disease Progression
Multivariate Analysis
Regression Analysis
Morbidity

Keywords

  • Brain natriuretic peptide
  • Heart failure
  • Prognosis
  • Trials

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. / Latini, Roberto; Masson, Serge; Wong, Maylene; Barlera, Simona; Carretta, Elisa; Staszewsky, Lidia; Vago, Tarciso; Maggioni, Aldo P.; Anand, Inder S.; Tan, Lip B.; Tognoni, Gianni; Cohn, Jay N.

In: American Journal of Medicine, Vol. 119, No. 1, 01.2006.

Research output: Contribution to journalArticle

Latini, R, Masson, S, Wong, M, Barlera, S, Carretta, E, Staszewsky, L, Vago, T, Maggioni, AP, Anand, IS, Tan, LB, Tognoni, G & Cohn, JN 2006, 'Incremental prognostic value of changes in B-type natriuretic peptide in heart failure', American Journal of Medicine, vol. 119, no. 1. https://doi.org/10.1016/j.amjmed.2005.08.041
Latini, Roberto ; Masson, Serge ; Wong, Maylene ; Barlera, Simona ; Carretta, Elisa ; Staszewsky, Lidia ; Vago, Tarciso ; Maggioni, Aldo P. ; Anand, Inder S. ; Tan, Lip B. ; Tognoni, Gianni ; Cohn, Jay N. / Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. In: American Journal of Medicine. 2006 ; Vol. 119, No. 1.
@article{0c55a9ace6e1431abf857bee42157a53,
title = "Incremental prognostic value of changes in B-type natriuretic peptide in heart failure",
abstract = "PURPOSE: B-type natriuretic peptide is one of the most sensitive and specific biohumoral markers of heart failure. We hypothesized that B-type natriuretic peptide changes during treatment of heart failure may provide independent information on disease progression and outcome in patients enrolled in the Val-HeFT trial. METHODS: Patients were divided into four groups according to concentrations of B-type natriuretic peptide at baseline versus 4 months (n = 3740) or 12 months (n = 3343), with respect to the baseline median (97 pg/mL): low→low (stable below median, 44{\%}-46{\%}), high→high (stable above median, 32{\%}-37{\%}), high→low (above to below median, 12{\%}-14{\%}), and low→high (below to above median, 6{\%}-9{\%}). Cox multivariate regression analysis was used to assess the risk of death and morbidity, with adjustment for baseline B-type natriuretic peptide concentrations. RESULTS: Patients who improved their B-type natriuretic peptide at 4 months (high→low) had a similar risk for mortality (hazard ratio = 1.191, 95{\%} confidence interval [CI] 0.870-1.631, P =.2746) compared with the low→low patients. Conversely, patients who worsened in their B-type natriuretic peptide (low→high) had a risk for mortality (hazard ratio 2.578, CI, 1.861-3.571, P 2 increase in left ventricular end-diastolic diameter, whereas it decreased by 0.10 cm/m2 in high→low and low→low groups (P",
keywords = "Brain natriuretic peptide, Heart failure, Prognosis, Trials",
author = "Roberto Latini and Serge Masson and Maylene Wong and Simona Barlera and Elisa Carretta and Lidia Staszewsky and Tarciso Vago and Maggioni, {Aldo P.} and Anand, {Inder S.} and Tan, {Lip B.} and Gianni Tognoni and Cohn, {Jay N.}",
year = "2006",
month = "1",
doi = "10.1016/j.amjmed.2005.08.041",
language = "English",
volume = "119",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Incremental prognostic value of changes in B-type natriuretic peptide in heart failure

AU - Latini, Roberto

AU - Masson, Serge

AU - Wong, Maylene

AU - Barlera, Simona

AU - Carretta, Elisa

AU - Staszewsky, Lidia

AU - Vago, Tarciso

AU - Maggioni, Aldo P.

AU - Anand, Inder S.

AU - Tan, Lip B.

AU - Tognoni, Gianni

AU - Cohn, Jay N.

PY - 2006/1

Y1 - 2006/1

N2 - PURPOSE: B-type natriuretic peptide is one of the most sensitive and specific biohumoral markers of heart failure. We hypothesized that B-type natriuretic peptide changes during treatment of heart failure may provide independent information on disease progression and outcome in patients enrolled in the Val-HeFT trial. METHODS: Patients were divided into four groups according to concentrations of B-type natriuretic peptide at baseline versus 4 months (n = 3740) or 12 months (n = 3343), with respect to the baseline median (97 pg/mL): low→low (stable below median, 44%-46%), high→high (stable above median, 32%-37%), high→low (above to below median, 12%-14%), and low→high (below to above median, 6%-9%). Cox multivariate regression analysis was used to assess the risk of death and morbidity, with adjustment for baseline B-type natriuretic peptide concentrations. RESULTS: Patients who improved their B-type natriuretic peptide at 4 months (high→low) had a similar risk for mortality (hazard ratio = 1.191, 95% confidence interval [CI] 0.870-1.631, P =.2746) compared with the low→low patients. Conversely, patients who worsened in their B-type natriuretic peptide (low→high) had a risk for mortality (hazard ratio 2.578, CI, 1.861-3.571, P 2 increase in left ventricular end-diastolic diameter, whereas it decreased by 0.10 cm/m2 in high→low and low→low groups (P

AB - PURPOSE: B-type natriuretic peptide is one of the most sensitive and specific biohumoral markers of heart failure. We hypothesized that B-type natriuretic peptide changes during treatment of heart failure may provide independent information on disease progression and outcome in patients enrolled in the Val-HeFT trial. METHODS: Patients were divided into four groups according to concentrations of B-type natriuretic peptide at baseline versus 4 months (n = 3740) or 12 months (n = 3343), with respect to the baseline median (97 pg/mL): low→low (stable below median, 44%-46%), high→high (stable above median, 32%-37%), high→low (above to below median, 12%-14%), and low→high (below to above median, 6%-9%). Cox multivariate regression analysis was used to assess the risk of death and morbidity, with adjustment for baseline B-type natriuretic peptide concentrations. RESULTS: Patients who improved their B-type natriuretic peptide at 4 months (high→low) had a similar risk for mortality (hazard ratio = 1.191, 95% confidence interval [CI] 0.870-1.631, P =.2746) compared with the low→low patients. Conversely, patients who worsened in their B-type natriuretic peptide (low→high) had a risk for mortality (hazard ratio 2.578, CI, 1.861-3.571, P 2 increase in left ventricular end-diastolic diameter, whereas it decreased by 0.10 cm/m2 in high→low and low→low groups (P

KW - Brain natriuretic peptide

KW - Heart failure

KW - Prognosis

KW - Trials

UR - http://www.scopus.com/inward/record.url?scp=30944450154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30944450154&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2005.08.041

DO - 10.1016/j.amjmed.2005.08.041

M3 - Article

VL - 119

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 1

ER -